Kornimate/medical-research-clean huggingface dataset:
pasconal nerventropfen in the treatment of nervous diseases

Conditions: Nervousness; Sleep Disorders

Summary: the purpose of this observational study is to give an overview of the use of pasconal nerventropfen in a 2-4 week treatment of nervous diseases, especially sleep disorders due to nervousness.

the purpose of this observational study is to give an overview of the use of pasconal nerventropfen in a 2-4 week treatment of nervous diseases, especially sleep disorders due to nervousness. efficacy and tolerability of the drug will be assessed. special regard will be taken to the administration management, dose regimen, and to the effectiveness and safety in special patient groups (children 1-12 years of age), in relation to treatment conformity to the summary of product characteristics (smpc).

Eligibility criteria:
due to the design as an observational study no inclusion or exclusion criteria for therapy are named. the included patient group is described under "cohort / group". observational criteria (=inclusion criteria for documentation): * males and females * children 1-12 years old * adults \>12 years old * suffering from nervous diseases, e.g. sleep disorders due to nervousness. exclusion criteria for documentation: * children younger than 1 year * no nervous diseases, e.g. sleep disorders due to nervousness. * no treatment with pasconal nerventropfen

Keywords: pasconal nervousness nervosity sleep disorder
causes associated with small fiber neuropathy (sfn).

Conditions: Small Fiber Neuropathy

Summary: small fiber neuropathy (sfn) is an injury of cutaneous nerve fibers, mainly by a decrease in their density within the cutaneous tissue. the symptomatology associated with this sfn is broad with symptoms that are essentially sensory, but also autonomic. the etiologies of sfn are numerous (diabetes, drug, infectious, immunological...) and clinically non-specific, justifying a broad etiological assessment. the appearance of staged skin biopsies in the sfn balance sheet has greatly helped to improve diagnosis. despite this, a significant part of sfn remains without associated etiology and is considered idiopathic. as the distribution of the different causes of sfn remains a missing data to date, the completion of this cohort study by one of the sfn reference centres should make it possible to establish the prevalence of sfn causes over a large population. only patients with clinical symptoms that may be related to sfn and who have been sampled for sfn, positive or not, will be eligible for recruitment. the result of the anatomopathological sampling will allow patients to be separated into two groups, with or without sfn. the main judgement criteria will be the prevalence of etiologies associated with sfn: diabetes, medication, systemic lupus erythematosus, gougerot-sjögren syndrome, amylosis, dysthyroidism, alcoholism, vitamin b12 deficiency, hiv infection, hepatitis c, paraneoplastic syndrome, hereditary disease (fabry disease, friedreich ataxia,...), idiopathic, others.


Eligibility criteria:
inclusion criteria: * age of majority (\>18 years old) * clinically managed patient at brest university hospital * patient who had a skin biopsy with anatomopathological examination for sfn performed at the university hospital of brest exclusion criteria: * under age of majority (\<18 years old) * patient not followed at brest university hospital * refusal to participate to the study
perception of electrical stimuli in individuals with stroke

Conditions: Stroke

Summary: to successfully manipulate objects in one's surroundings, such as when lifting a cup, one must accurately perceive their physical interactions. this includes accurately interpreting the tactile cues arising at one's fingertips when touching an object. currently, tactile perception is assessed in individuals with stroke using passive protocols. research has yet to explore whether activating one's muscles impacts the tactile perceptual process in individuals with stroke despite previous research demonstrating the effect of muscle activation on tactile perception in individuals who are neurologically intact. the proposed research will be the first to address the impact of muscle activation, in addition to stroke, on tactile perception. as such, the proposed research is significant for advancing our understanding of the extent to which tactile deficits occur in individuals with stroke, particularly during volitional movement.

participants will detect an externally-applied electrical stimulus at their fingertip with the elbow: 1) relaxed and flexed to 2) 25% and 3) 50% of their maximum voluntary torque (mvt). we will compare the detection threshold for these three conditions between each arm of participants with stroke and similarly-aged controls. based on pilot data, we hypothesize that the detection threshold will be largest at the paretic arm when flexing to 50% mvt due to the greatest inhibition of sensory signals. findings will indicate whether stroke negatively impacts an individual's ability to detect tactile stimuli during volitional sensorimotor tasks.

Eligibility criteria:
inclusion criteria: * for the participants with stroke, i) a single unilateral cortical lesion that took place at least one year prior and ii) an absence of comorbid neurological impairments * ability to understand and complete the experimental tasks * capacity to provide informed consent * at least 18 years of age exclusion criteria: * major injury to either arm * sensory neuropathy

Keywords: tactile perception somatosensation muscle activation
a study of tyrosine kinase inhibitor orelabrutinib (icp-022) in patients with r/r b-cell malignancies

Conditions: Part 1：r/r B-cell Malignancies; Part 2：B-cell Malignancies

Summary: this is a phase i/ii, multicenter, open-label study to evaluate the safety, efficacy, tolerability, and pharmacokinetics of a novel btk inhibitor, orelabrutinib (icp-022) in patients with b-cell malignancies. the study contains two parts, part 1 (dose escalation) and part 2 (dose expansion).


Eligibility criteria:
inclusion criteria: 1. signed informed consent. 2. age ≥ 18 years. 3. part 1: patients with histologically confirmed relapsed or refractory b-cell malignancies, including grades 1-3a fl, mzl, mcl, and cll/sll. part 2: patients with histologically confirmed b-cell malignancies including r/r fl, r/r mzl and cll/sll with/without prior treatment. 4. life expectancy (in the opinion of the investigator) of ≥ 4 months. 5. ecog performance status of 0 \~1. 6. must have adequate organ function. 7. negative test results for hbv (\[hbsag (-)\] and non-active hbv or hcv infection exclusion criteria: 1. pregnant or breast-feeding or intending to become pregnant during the study. 2. prior treatment with systemic immunotherapeutic agents. 3. known allergies to orelabrutinib (icp-022) or its excipients or infection with hiv. 4. treatment with any chemotherapeutic agent, or any other investigational therapies within 4 weeks prior to first dose of the study drug. 5. history of allogeneic stem-cell (or other organ) transplantation or confirmed progressive pml. 6. any external beam radiation therapy within 6 weeks prior to the first dose of the study drug. 7. concurrent use of warfarin or other vitamin k antagonists or anticoagulation therapies or strong cyp3a inhibitor. 8. active uncontrolled infections. 9. recent infection requiring iv anti-infective treatment that was completed ≤ 14 days before the first dose of study drug. 10. unresolved toxicities from prior anti-cancer therapy. 11. medically apparent cns lymphoma or leptomeningeal disease. 12. current or previous history of cns disease. 13. major surgery or significant traumatic injury \< 28 days prior to the first dose of the study drug. 14. patients with another invasive malignancy in the last 2 years. 15. significant cardiovascular disease or active pulmonary disease. 16. received systemic immunosuppressive medications.
gud clinical and virologic response to acyclovir in hiv negative african women

Conditions: Genital Herpes

Summary: to examine the time to healing of genital lesion and duration of herpes simplex virus (hsv) shedding from genetic ulcer disease (gud) among 90 hiv-negative african women who have a history of gud and are hsv-2 seropositive and hiv-1 seronegative randomized in a 2:1 ratio to receive episodic acyclovir 400mg orally three times daily or matching placebo three times daily for 5 days and who are followed for a total of 13 days.


Eligibility criteria:
inclusion criteria: * hiv negative as determined by concordant rapid testing * hsv-2 seropositive (focus herpeselect \>3.4) * at least one prior occurrence of gud * 18-50 years of age exclusion criteria: * current use, or use w/in past 7 days of acyclovir, valacyclovir, or famciclovir * prior hypersensitivity \&/or allergic reaction to acyclovir * use of probenicid * current use, or use within past 28 days, of an investigational agent * currently pregnant or nursing * currently plan to become pregnant during next 3 months * any condition that will interfere with successful completion of study procedures

Keywords: herpes simplex virus acyclovir hsv shedding women africa
postoperative conformal radiotherapy for stage ii-iii b type thymoma

Conditions: Thymoma

Summary: the purpose of this study is to determine whether postoperative conformal radiotherapy are effective in the treatment of masaoka stage ii-iii b type thymoma.

the role of postoperative radiotherapy in thymoma is controversial. some retrospective studies were for the radiotherapy, but others were against. however, more inherent biases existed in these trials. resection, masaoka stage and pathology were widely accepted as the prognostic factors for thymoma. furthermore, the frequency of local failure after radical resection was still high in masaoka stage ii-iii b type thymoma. with the conformal technique appearing, conformal radiotherapy can escalate the dose without increasing the risk of normal tissue toxicities.

Eligibility criteria:
inclusion criteria: * age 18-75, zubrod-ecog-who 0-2, the interval of surgery to radiotherapy \< 2months, masaoka stage ii-iii and who b type thymoma exclusion criteria: * no second primary tumor, no serious comorbidity, no neoadjuvant anticancer treatment, no adjuvant chemotherapy.

Keywords: postoperative conformal radiotherapy thymoma
the effect of nb-uvb on interleukin-36 levels in psoriasis

Conditions: Psoriasis

Summary: psoriasis is an immune-mediated skin disease that affects 1-2 % of the population. several cytokines have been found to be involved in the complex pathogenesis of this disease. il- 36 is one of the cytokines sharing in psoriasis pathogenesis, as its levels are elevated in psoriatic plaques. cathepsin g is known to activate il- 36 and promote inflammation in psoriasis.nb-uvb is one of the important treatment modalities for psoriasis. the aim of this study is to detect the effect of nb-uvb on the lesional levels of il-36 in psoriasis.

25 psoriasis patients will receive 26 sessions of phototherapy (nb-uvb). patients will receive 3 sessions per week. tissue levels of il-36 and cathepsin g will be assessed in skin lesions before starting treatment and after completing the 26 sessions.

Eligibility criteria:
inclusion criteria: * patients with psoriasis vulgaris of both sexes * age between 18 and 60 years old. exclusion criteria: * pregnant females * patients receiving systemic treatment or topical treatment for psoriasis within the past two months. * patients having other dermatological diseases.
effect of saxagliptin on pre-diabetes mellitus and obesity

Conditions: Prediabetes

Summary: the purpose of the study is to examine the effect of saxagliptin in the newly diagnosed people with pre-diabetes and obesity besides lifestyle intervention ,there to evaluate dpp 4 inhibitors of reversing pre-diabetes curative effect to normal blood sugar, and observe its influences on the targets of obesity related metabolic abnormalities, to explore new ways for intervention on populations with pre-diabetes and obesity .

materials and methods: this is a perspectiveness ,randomized, opening study, patients will be randomly assigned to the standarddose saxagliptin group ,the lifestyle intervention group,the metformin group and the low dose saxagliptin group with a 6-month treatment period. oral glucose tolerance test will examined before and 6 months post-treatment during the trial.

Eligibility criteria:
inclusion criteria: 1.newly diagnosed insulin resistance or glucose intolerance . 2.20 to 70 years of age. 3.bmi≥28kg/m2，or bmi\>25kg/m2 beside waistline≥80cm（female)，≥90cm(male). exclusion criteria: 1. under diabetes mellitus treatment. 2. allergy to dipeptidyl peptidase 4 (dpp-4) inhibitors . 3. active heart failure. 4. unwilling or unable to sign inform consents.

Keywords: saxagliptin, prediabetes, glucose intolerance,obesity
efficacy investigation study of olopatadine hydrochloride ophthalmic solution using ohio chamber in patients with seasonal allergic rhinitis (sar)

Conditions: Allergic Conjunctivitis

Summary: to evaluate the efficacy of olopatadine 0.1% using the ohio chamber in patients with seasonal allergic conjunctivitis.


Eligibility criteria:
inclusion criteria: 1. age/gender: males and females aged \>20 to \< 65 years (at the time of obtaining consent). 2. positive cases in whom blood specific ige antibody quantification against cedar pollen showed class 2-6 in a health checkup conducted within the past 3 years. 3. cases who were diagnosed as patients with seasonal allergic conjunctivitis and were judged eligible as subjects of the said study by the investigator or co-investigator from the results of medical examination conducted on the day of the study or prior to it. 4. cases who gave consent on study participation of their own free will in writing, with understanding the contents of the said study. exclusion criteria: 1. cases with an ocular disease that requires treatment other than allergic conjunctivitis. 2. cases with an inflammatory ocular disease in the external/anterior part of the eye that may affect drug efficacy evaluation. 3. cases with a respiratory disease such as bronchial asthma other than allergic rhinitis. 4. cases with past history of anaphylaxis. 5. cases with past history of hypersensitivity to olopatadine hydrochloride/tranilast. 6. cases undergoing immunotherapy (hyposensitization therapy; modulated therapy). 7. patients who are pregnant, lactating women, or may be pregnant, or cases wishing to be pregnant during the study period. 8. other cases who are judged ineligible for participation in the main study by the doctor in charge of the study.

Keywords: conjunctivitis
additional effects of vagus nerve stimulation on motor functions of upper-limb in stroke

Conditions: Stroke (CVA) or TIA

Summary: the study aims to determine the additional effects of vagus nerve stimulation with task-oriented training on motor functions of upper-limb in stroke

stroke is a clinical syndrome characterized by rapidly developing clinical signs of focal (or global) disturbance of cerebral function lasting more than 24 hours or leading to death with no apparent cause. nerve stimulation paired with rehabilitation is a novel potential treatment option for people with long-term moderate-to-severe arm impairment after stroke. the study aims to determine the additional effects of vagus nerve stimulation with task-oriented training on motor functions of upper-limb in stroke. the idea of stimulating the vagus nerve to modify central brain activity has been pursued. vagus nerve stimulation (vns) paired with rehabilitative training enhances recovery of function in models of stroke and is currently under investigation for use in chronic stroke patients. compared to traditional stimulation, noninvasive vns seems to be safer and more tolerable.

Eligibility criteria:
inclusion criteria: * sub-acute stroke (3 months to 6 months) * between grade 0 and grade 2 on modified ashworth scale. * patients who will be able to walk without assisted devices and can stand for 2 minutes. * either type ischemic or hemorrhagic * age bracket 40-60 years exclusion criteria: * previous surgical intervention on vagus nerve * severe pain in upper extremity * moca score of less than 10

Keywords: impairement stroke task oriented upper limb vagus nerve
novel treatment delivery of ecap-controlled closed-loop scs for chronic pain

Conditions: Chronic Pain

Summary: the purpose of this study is to test and evaluate novel treatment delivery of ecap-controlled closed loop scs through the incorporation of new software and/or hardware features for patients with the evoke system.


Eligibility criteria:
inclusion criteria: * 1. subject has undergone trial implant or is planning to be implanted with the evoke system within its approved indication. * 2. subject is willing and capable of giving informed consent and able to comply with study-related requirements. exclusion criteria: n/a
"assessing the impact of personalized music playlists on procedural anxiety and crown preparation performance among young dentists: a randomized controlled trial"

Conditions: Crown; Procedural Anxiety

Summary: the objective of this study was to evaluate the effectiveness of personalized music playlists in reducing procedural anxiety among young dentists performing crown preparations for porcelain-fused-to-metal (pfm) crowns. a randomized controlled trial with a parallel-group design was conducted at the department of prosthodontics, school of dentistry, shaheed zulfiqar ali bhutto medical university, from april 12th, 2024, to october 11th, 2024. a total of 64 young dentists (20-30 years old) were randomly assigned to two groups: the experimental group (group a), which listened to personalized music during the procedure, and the control group (group b), which received no music. anxiety was measured using the state-trait anxiety inventory (stai) before and after the procedure. physiological parameters, including heart rate and respiratory rate, were also monitored. the preparation was evaluated based on a structured scoring rubric, assessing critical parameters. the scoring was conducted by two experienced prosthodontists who were blinded to the participant's group allocation. statistical analysis was performed using spss version 25.0.0, with a p-value of \<0.05 considered statistically significant.


Eligibility criteria:
inclusion criteria: * both male and female * young dentists 20-30 years. * recently graduated from dental school. (graduated within the last 1-3 years.) * no hearing impairments or known psychiatric disorders. exclusion criteria: * dentists with previous experience in anxiety management techniques. * those who have already participated in similar studies.
a research study to compare two types of insulin: insulin 287 and insulin glargine in people with type 2 diabetes who have not used insulin before

Conditions: Diabetes Mellitus, Type 2

Summary: this study compares insulin 287 (a possible new medicine) to insulin glargine (a medicine doctors can already prescribe) in people with type 2 diabetes. different ways of changing the dose of insulin 287 are also compared. this is done to find the best way to change the dose of insulin 287. participants will either get insulin 287 that they will have to inject once a week or insulin glargine that participants will have to inject once a day. which treatment participants get is decided by chance. the study will last for about 5 months (23 weeks). participants will have 14 clinic visits and 6 phone calls with the study doctor. at 3 of the clinic visits participants will be asked not to eat or drink anything (except for water) in the last 8 hours before the visit. during the study, the study doctor will ask participants to: * measure blood sugar every day with a blood sugar meter using a finger prick. * write down different information in a diary daily and return this to the study doctor. * wear a medical device (sensor) that measure blood sugar all the time for 18 weeks (about 4 months) during the study. women cannot take part if pregnant, breastfeeding or plan to become pregnant during the study period.


Eligibility criteria:
inclusion criteria: * male or female, aged 18-75 years (both inclusive) at the time of signing informed consent * diagnosed with type 2 diabetes mellitus greater than or equal to 180 days prior to the day of screening * hba1c of 7.0-10.0% (53.0-85.8 mmol/mol) (both inclusive) as assessed by central laboratory * stable daily dose(s) for 90 days prior to the day of screening of any of the following antidiabetic drug(s) or combination regime(s): 1. any metformin formulations greater than or equal to 1500 mg or maximum tolerated or effective dose (as documented in subject's medical records) 2. free or fixed combination therapy: metformin as outlined above plus/minus dpp4i with or without sglt2i is allowed: i) dpp4i (greater than or equal to half of the maximum approved dose according to local label or maximum tolerated or effective dose) ii) sglt2i (greater than or equal to half of the maximum approved dose according to local label or maximum tolerated or effective dose ) * insulin-naïve. however, short term insulin treatment for a maximum of 14 days prior to the day of screening is allowed, as is prior insulin treatment for gestational diabetes * body mass index (bmi) below or equal to 40.0 kg/m\^2